213 related articles for article (PubMed ID: 23305699)
1. Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Vijayaraghavalu S; Labhasetwar V
Cancer Lett; 2013 Apr; 331(1):122-9. PubMed ID: 23305699
[TBL] [Abstract][Full Text] [Related]
2. Circumvention of drug-resistance via decitabine-mediated DNMT1 depletion.
Torres-Collado AX; Jazirehi AR
Epigenomics; 2013 Jun; 5(3):253-54. PubMed ID: 24303552
[No Abstract] [Full Text] [Related]
3. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
4. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Vijayaraghavalu S; Labhasetwar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019
[TBL] [Abstract][Full Text] [Related]
5. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
7. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
8. Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells.
Adams PD; Cairns P
Cancer Biol Ther; 2003; 2(5):557-8. PubMed ID: 14614326
[No Abstract] [Full Text] [Related]
9. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
10. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
[TBL] [Abstract][Full Text] [Related]
11. The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Yan F; Shen N; Pang J; Molina JR; Yang P; Liu S
J Biol Chem; 2015 Jul; 290(30):18480-94. PubMed ID: 26085088
[TBL] [Abstract][Full Text] [Related]
12. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.
Yan L; Nass SJ; Smith D; Nelson WG; Herman JG; Davidson NE
Cancer Biol Ther; 2003; 2(5):552-6. PubMed ID: 14614325
[TBL] [Abstract][Full Text] [Related]
14. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
15. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
16. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
17. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
Ghoshal K; Datta J; Majumder S; Bai S; Kutay H; Motiwala T; Jacob ST
Mol Cell Biol; 2005 Jun; 25(11):4727-41. PubMed ID: 15899874
[TBL] [Abstract][Full Text] [Related]
18. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
[TBL] [Abstract][Full Text] [Related]
19. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
20. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Ando T; Nishimura M; Oka Y
Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]